{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "RZLT",
  "name": "Rezolute, Inc.",
  "url": "https://frontierpicks.com/dossiers/RZLT/",
  "json_url": "https://frontierpicks.com/dossiers/RZLT.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "A 10.7% week to $5.09 on 2026-08-21 with zero company news since the 2026-07-21 conference notice — the bid arrived via Friday-gainer screens, not a disclosure. The 2026-06-02 upLIFT interim (6 of 8 responders) is still the entire story, the topline is still undated inside \"2H-2026\", and the ~2026-09-16 FY2026 report is the only dated event in the window.",
  "invalidation_trigger": "A weekly close below $4.55 puts price back under the $4.60/$4.61 shelf that held 2026-07-17 to 2026-08-14 and reads the August move as screener flow; below $4.00 closes the 2026-06-02 interim gap. Secondary: the FY2026 report (~2026-09-16 est.) passing without dating the upLIFT topline, or an equity takedown ahead of it.",
  "catalyst_date": "2026-09-16",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "binary-catalyst-biotech",
    "rare-disease-gene-therapy",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Single-asset binary: valuation resolves on the upLIFT full topline, guided only to 2H-2026 and still undated as of 2026-08-23.",
    "The same antibody missed Phase 3 sunRIZE in congenital HI on 2025-12-11; upLIFT differs in indication, endpoint (IV glucose infusion rate) and design.",
    "Fiscal year ends June 30. The FY2026 10-K and full-year business update typically land mid-September; the 2026 date is not company-confirmed.",
    "Cash and investments $120.3M at 2026-03-31 against a $16.2M quarterly net loss; the 2026-06-30 figure is unpublished until the FY2026 report.",
    "Prior financings used registered common stock plus pre-funded warrants; any takedown before topline would be dilution against a chart 53.5% below its 52-week high.",
    "Microcap, no revenue and no approved product; liquidity thins between event dates and headline gaps can be wide in both directions."
  ],
  "body_markdown": "\n> # RZLT — Rezolute, Inc.\n\n## Current Thesis\nThe leg on offer has not changed since June: ersodetug (RZ358) clearing a *registrational* single-arm Phase 3 in tumor hyperinsulinism, an ultra-rare indication with no approved therapy, in a study the FDA already accepted (agreement reached August 2025, disclosed 2025-11-06) as the adequate and well-controlled trial to support a filing. What has changed is the tape, not the information. After four weeks pinned within a cent — $4.61 on 2026-07-17, $4.60 on 2026-08-14 — the stock closed $5.09 on 2026-08-21, a 10.7% move over five sessions, and RSI(14) lifted from 37.9 to 57.0. No company release accompanied it. Rezolute's investor newsroom shows nothing after the 2026-07-21 BTIG conference-participation notice; the last clinical datapoint is 2026-06-17. The move showed up in a Benzinga screener round-up of Friday gainers alongside MARA Holdings, Coinbase Global and Ternium, and in a momentum-blog write-up dated 2026-08-22 framed around cash runway and volatility. That is what the advance is built on so far: attention arriving through movers lists, with the same 6-of-8 interim underneath it and the topline still guided only to \"second half of 2026.\"\n\n## Bull Case\n- **The interim is measured, not reported by patients.** 2026-06-02: 6 of 8 enrolled participants met the primary endpoint — at least a 50% reduction in IV glucose infusion rate over eight weeks — and all six discontinued IV glucose entirely. Glucose infusion rate is a hospital-recorded variable, which sidesteps the placebo-response problem that sank the self-reported symptom endpoint in sunRIZE.\n- **The filing path was negotiated before the data.** Per the fiscal Q1 2026 update (2025-11-06), the FDA agreed in August 2025 that a truncated, single-arm, open-label Phase 3 in up to 16 hospitalized participants is acceptable for registration in tumor HI, removing the randomized double-blind requirement. Topline-to-submission is therefore a short distance if the responder rate holds.\n- **No sell-side target has been cut in eleven weeks.** The June actions — HC Wainwright Buy/$5 (2026-06-02), Citizens JMP upgrade to Market Outperform/$11, Maxim $14, Wedbush $6 (all 2026-06-03), Guggenheim Buy/$11 (2026-06-15) — all sit above the 2026-08-21 close of $5.09, and the coverage feed shows no revision in either direction since 2026-06-15.\n- **Funded through the event on the last published figure.** $120.3M in cash and investments at 2026-03-31 against a fiscal Q3 net loss of $16.2M (reported 2026-05-12, EPS −$0.16 versus −$0.17 consensus). At that burn the company is not structurally forced to finance before topline — though the 2026-06-30 number is unpublished until the FY2026 report.\n- **Supporting real-world signal.** At ENDO (2026-06-17), 75% of tumor-HI expanded-access patients on IV dextrose or TPN achieved complete discontinuation.\n\n## Bear Case\n- **The same antibody already failed a Phase 3.** sunRIZE in congenital HI missed on 2025-12-11: roughly 45% hypoglycemia-event reduction at the top dose versus roughly 40% on placebo, not statistically significant. The $10.94 52-week high predates that print; the 2026-08-21 close is 53.5% below it.\n- **Eight patients is eight patients.** Open-label, single-arm, up to 16 planned, with the company describing itself as midway through enrollment on 2026-06-02. The unenrolled half can move the final responder proportion, and the confidence bounds around a six-responder read are wide however the tape treated them.\n- **The advance is not attached to a disclosure.** Between 2026-06-17 and 2026-08-23 the only company communication is a conference-participation release (2026-07-21). The BTIG event on 2026-07-28/29 passed without a price response. A 10.7% week on no company news is a positioning event until something dates it.\n- **The topline still has no date.** \"2H-2026\" has been the guide since 2025, and no 8-K announcing completion of upLIFT enrollment has appeared. Without that marker the window can only drift toward the far edge of the guide.\n- **Financing optionality cuts against holders.** Prior raises used registered common plus pre-funded warrants. A takedown before topline would price dilution against a chart still down more than half from its high.\n\n## Setup & Price Structure\nReference close 2026-08-21: $5.09. Three-month price change +56.6%; distance from the 52-week high of $10.94 is −53.5%; RSI(14) 57.0. The structure since the 2026-06-02 gap is a wide shelf, not a trend: the tape spent 2026-07-17 to 2026-08-14 essentially flat at $4.60/$4.61, then cleared it in the week ending 2026-08-21. The gap itself remains unfilled — the prior break level for that, a weekly close below $4.00, has not been approached.\n\nThe narrative is **maturing**. The dates support it. New attention arrived once, in the first week of June (2026-06-02 interim, four sell-side actions on 06-02/06-03, one more on 06-15) and stopped; the last clinical headline is 2026-06-17. Since then flow has moderated to zero company-driven news over nine weeks while price held the June gap and then extended. That is a narrative still working with no fresh fuel — neither the expanding participation of an accelerating theme nor the broken structure of a dead one. The label flips if the FY2026 report re-dates the topline and coverage restarts (accelerating), or if mainstream momentum coverage keeps building while the topline slips (saturated).\n\nCrowding and positioning observables, stated as observables: coverage of the name in the last week has been screener-derived rather than research-derived — a Friday-gainers list on 2026-08-21 and a retail-facing momentum post on 2026-08-22 built around runway and volatility. RSI(14) at 57.0 is mid-range, not stretched. There is no insider selling or registered takedown visible in the recent filing window. An estimated report date sits roughly three and a half weeks out. Price sits about 10% above a four-week shelf that produced two closes one cent apart.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-09-16 (est.)** — FY2026 fourth-quarter and full-year results plus business update, fiscal year ended 2026-06-30. Not company-confirmed; MarketBeat carries 2026-09-16 as its estimate, extrapolated from the 2025-09-17 prior-year report. This is the only dated item in the window and the most likely venue for cash at 2026-06-30, upLIFT enrollment status, and any narrowing of the topline guide.\n\n## Elapsed catalysts\n\n- **Undated, 2026** — an 8-K or release announcing completion of upLIFT enrollment (8 of up to 16 at the 2026-06-02 interim). The best available forward-timing marker for the readout. *(passed 85d ago)*\n- **2H-2026 (undated)** — upLIFT full topline in tumor HI. The binary. No calendar date exists for it as of 2026-08-23. *(passed 3d ago)*\n\n## What Would Change Our Mind\nThe structure that would have to fail first is the shelf the August advance cleared: two closes at $4.61 (2026-07-17) and $4.60 (2026-08-14) marking where the name sat for four weeks. A weekly close below $4.55 puts price back underneath it and reads the 2026-08-21 move as screener flow that found no follow-through; a weekly close below $4.00 would close the 2026-06-02 interim gap outright and say the 6-of-8 read is no longer being paid for at all.\n\nOn the fundamental side, three things would change the read independent of price. First, the FY2026 report (~2026-09-16 est.) passing without dating the upLIFT topline, or moving it beyond 2026 — that converts an undated catalyst into an absent one. Second, an S-3 takedown or offering priced ahead of the readout, which turns a funded binary into a diluted one. Third, any disclosure that the FDA has revisited the single-arm registrational path, since the August 2025 agreement is what makes a 16-patient open-label study worth a re-rating at all. In the other direction, an enrollment-completion release with a specific topline window would restore a dated event to a name that currently has none, and would be the cleanest reason to revisit the label.\n\n## Correlation Notes\n- On 2026-08-21 RZLT was grouped in a movers list with MARA Holdings, Coinbase Global and Ternium — crypto-adjacent and steel names with nothing in common except a high-beta risk-on session. That grouping is evidence the day's move rode a broad risk bid rather than a company-specific input.\n- Between event dates the name trades as microcap biotech beta: an XBI drawdown with no company headline is the most likely source of a break of the July–August shelf, and would not be information about ersodetug.\n- On the topline day the correlation goes to zero. A single-asset, single-endpoint readout in an ultra-rare indication is idiosyncratic by construction, and neither sector positioning nor the June gap will inform the direction of that gap.\n- The 2025-12-11 sunRIZE failure is the closest available analogue for how this shareholder base reacts to a negative primary-endpoint print from the same antibody; the 52-week high set before it has not been revisited since.",
  "first_seen": "2026-06-07",
  "last_analyzed": "2026-08-23T16:43:57+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}